Processing

Please wait...

Settings

Settings

Goto Application

1. WO1997033592 - METHODS FOR CELL MOBILIZATION USING IN VIVO TREATMENT WITH HYALURONAN (HA)

Publication Number WO/1997/033592
Publication Date 18.09.1997
International Application No. PCT/CA1997/000172
International Filing Date 12.03.1997
Chapter 2 Demand Filed 13.10.1997
IPC
A61K 31/728 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
726Glycosaminoglycans, i.e. mucopolysaccharides
728Hyaluronic acid
CPC
A61K 31/728
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
726Glycosaminoglycans, i.e. mucopolysaccharides
728Hyaluronic acid
A61P 37/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
Applicants
  • HYAL PHARMACEUTICAL CORPORATION [CA]/[CA] (AllExceptUS)
  • PILARSKI, Linda, May [US]/[CA] (UsOnly)
Inventors
  • PILARSKI, Linda, May
Agents
  • HUGHES, Etigson
Priority Data
2,173,27202.04.1996CA
60/013,40114.03.1996US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) METHODS FOR CELL MOBILIZATION USING IN VIVO TREATMENT WITH HYALURONAN (HA)
(FR) PROCEDES DE MOBILISATION CELLULAIRE A L'AIDE D'UN TRAITEMENT IN VIVO UTILISANT L'HYALURONAN (HA)
Abstract
(EN) The use of forms of hyaluronic acid having a molecular weight less than about 750,000 daltons selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof is provided for the same purposes known for using recombinant GM-CSF or G-CSF.
(FR) L'invention se rapporte à l'utilisation de formes de l'acide hyaluronique ayant un poids moléculaire inférieur à environ 750 000 daltons et sélectionnées dans le groupe constitué de l'acide hyaluronique et de ses sels pharmaceutiquement acceptables, ces formes étant destinées à être utilisées dans les mêmes buts que le GM-CSS ou G-CSS (facteur stimulant la colonie de granulocytes-macrophages) recombinant.
Latest bibliographic data on file with the International Bureau